M
Mahmut Gumus
Researcher at Istanbul Medeniyet University
Publications - 231
Citations - 8448
Mahmut Gumus is an academic researcher from Istanbul Medeniyet University. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 25, co-authored 200 publications receiving 5285 citations. Previous affiliations of Mahmut Gumus include Dicle University & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok,Yi-Long Wu,Iveta Kudaba,Dariusz M. Kowalski,Byoung Chul Cho,Hande Turna,Gilberto de Castro,Vichien Srimuninnimit,Konstantin Laktionov,Igor Bondarenko,Igor Bondarenko,Kaoru Kubota,Gregory M. Lubiniecki,Jin Zhang,Debra Kush,Gilberto Lopes,Gonzalo Gomez Aubin,Luis Enrique Fein,Diego Kaen,Ruben Dario Kowalyszyn,Guillermo Lerzo,Gaston Martinengo,Matias Molina,Eduardo Richardet,Pablo Picon,Mirta Varela,J. J. Zarba,Sergio J Azevedo,Carlos H. Barrios,Carlos Beato,Carlos Alexandre Sydow Cerny,Pedro Rafael Martins De Marchi,Gustavo Fernandes,Fabio Franke,Helano C. Freitas,Gustavo Girotto,Valeria Lopes,Lucas Vieira dos Santos,Marcos Andre Costa,Andrea Kazumi Shimada,Oren Smaletz,Joao Paulo Holanda Soares,Ana Paula Victorino,Carlos Ferreira,Marchela Koleva,Krassimir Koynov,Rumyana Micheva,Tsvetan Deliverski,Zhasmina Milanova,Boyan Doganov,Susanna Cheng,Flavia De Angelis,Giovanna Speranza,Rosalyn A. Juergens,Doran Ksienski,David Fenton,Osvaldo Rudy Aren,Christian Caglevic,Hector Galindo,Felipe Rey,Jianhua Chang,Gongyan Chen,Xi Chen,Xuenong Ouyang,Ying Cheng,Zhenyu Ding,Mei Hou,Yun Fan,Jifeng Feng,Jianxing He,Yong He,Yi Hu,Wei Li,Xiaoqing Liu,Zhe Liu,Shun Lu,Shukui Qin,Qiyou Tang,Bu-Hai Wang,Kai Wang,Li Zhang,Xin Zhang,Jun Zhao,Jie Wang,Caicun Zhou,Jianying Zhou,Qing Zhou,Andrés F. Cardona,Ricardo Duarte,Luis Gomez Wolff,Angela Zambrano,Marcela Vallejo,Libor Havel,Vitezslav Kolek,Petr Kolman,Leona Koubkova,Lubos Petruzelka,Patrice Popelkova,Jaromir Roubec,Jaroslav Vanasek,Tomas Vlasek,Jana Jaal,Gerli Kuusk,Oscar Avendano,Hugo Castro,Karla Lopez,Mario Sandoval,Chung Man James Ho,Sing Hung Lo,Ibolya Laczó,Bela Piko,Gyula Ostoros,Keisuke Aoe,Yasuhito Fujisaka,Tomonori Hirashima,Atsushi Horiike,Yukio Hosomi,Katsuyuki Hotta,Masao Ichiki,Fumio Imamura,Yasuo Iwamoto,Kazuo Kasahara,Nobuyuki Katakami,Terufumi Kato,Shuji Murakami,Tomoya Kawaguchi,Kazuma Kishi,Takayasu Kurata,Yoshitaro Torii,Yasuharu Nakahara,Takashi Nishimura,Tatsuo Ohira,Hideo Saka,Toshiyuki Sawa,Nobuhiko Seki,Shunichi Sugawara,Kazuhisa Takahashi,Nagio Takigawa,Hiroshi Tanaka,Kazuhiko Yamada,Takuma Yokoyama,Toshihide Yokoyama,Hiroshige Yoshioka,Gunta Purkalne,Zinaida Stara,Alvydas Cesas,Saulius Cicenas,Marius Zemaitis,Soon Hin How,Chong-Kin Liam,Choo Khoon Ong,Lye Mun Tho,Oscar Arrieta Rodriguez,Carlos Hernandez Hernandez,Luis Mas,Luis Vera,Jorge Salas,Hermes Tejada,Regina Edusma-Dy,Christina Galvez,Guia Ladrera,Jerry Tan Chun Bing,Jacek Jassem,Ewa Kalinka-Warzocha,Boguslawa Karaszewska,Andrzej Kazarnowicz,Krzysztof Lesniewski Kmak,Rodryg Ramlau,António Araújo,Fernando Barata,Nuno Gil,Venceslau Hespanhol,A. Alexandru,Mircea Dediu,Nelly Cherciu,Daniel Ciurescu,Doina Ganea,Lucian Miron,Daniela Sirbu,Maria Turdean,Sergey Emelyanov,Nina Karaseva,Lyudmila Kuzina,Sergey Lazarev,Igor Dmitrievich Lifirenko,Larisa Bolotina,Oleg Lipatov,Elena Ovchinnikova,Marina Matrosova,Anna Alyasova,Artem Poltoratsky,Pavel Taranov,Oleg Zarubenkov,Graham Cohen,Lydia Dreosti,Freddy Seolwane,Jacqueline Hall,Gregory Hart,Christa Jordaan,Sayeuri Buddu,Michiel Botha,Gregory Landers,Bernardo Rappaport,Paul Ruff,Lucinda Shepherd,Waldemar Szpak,Myung-Ju Ahn,Joo Hang Kim,Per Bergstrom,Ronny Ohman,Hakan Griph,Daniel Betticher,Adrian F. Ochsenbein,Alfred Zippelius,Gee Chen Chan,Chao Hua Chiu,Te Chun Hsia,Wu Chou Su,Chih-Hsin Yang,Touch Ativitavas,Pongwut Danchaivijitr,Kasan Seetalarom,Aumkhae Sookprasert,Virote Sriuranpong,Ozden Altundag,Filiz Cay Senler,Mustafa Erman,Tuncay Göksel,Erdem Göker,Ozgur Ozyilkan,Mesut Seker,Mahmut Gumus,Fulden Yumuk,Grigory Adamchuk,Oleksandr Ivashchuk,Olga Ponomarova,Andrii Rusyn,Sergii Shevnya,Yaroslav Shparyk,Ivan Sinielnikov,Orest Andrusenko,Dmytro Trukhyn,Grygoriy Ursol,Ihor Vynnychenko,Tien Quang Nguyen,Xuan Dung Pham +245 more
TL;DR: Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations, and the benefit-to-risk profile suggests that first-line pembrology monotherapy can be extended as first line therapy for locally advanced or metastatic non-small-cell lung cancer patients with sensitising EGFR or ALK translocation.
Journal ArticleDOI
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D. Galsky,Jose Angel Arranz Arija,Aristotelis Bamias,Ian D. Davis,Maria De Santis,Eiji Kikuchi,Xavier Garcia-del-Muro,Ugo De Giorgi,Marina Mencinger,Kouji Izumi,Stefano Panni,Mahmut Gumus,Mustafa Ozguroglu,Arash Rezazadeh Kalebasty,Se Hoon Park,Boris Alekseev,Fabio A.B. Schutz,Jian Ri Li,Dingwei Ye,Nicholas J. Vogelzang,Sandrine Bernhard,Darren Tayama,Sanjeev Mariathasan,Almut Mecke,Ann Christine Thastrom,Enrique Grande +25 more
TL;DR: The results of IMvigor130 support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma and the safety profile of the combination was consistent with that observed with the individual agents.
Journal ArticleDOI
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Ahmet Sezer,Saadettin Kilickap,Mahmut Gumus,Igor Bondarenko,Mustafa Ozguroglu,Miranda Gogishvili,Haci Mehmet Turk,Irfan Cicin,Dmitry Bentsion,Oleg Gladkov,Philip Clingan,Virote Sriuranpong,Naiyer A. Rizvi,Bo Gao,Siyu Li,S. Lee,Kristina McGuire,Chieh I. Chen,Tamta Makharadze,Semra Paydas,Marina Nechaeva,Frank Seebach,David M. Weinreich,George D. Yancopoulos,Giuseppe Gullo,Israel Lowy,P. Rietschel +26 more
TL;DR: In this paper, the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50% was examined in a multicentre, open-label, global, phase 3 study.
Journal ArticleDOI
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Charles M. Rudin,Mark M. Awad,Alejandro Navarro,Maya Gottfried,Solange Peters,Tibor Csőszi,Parneet Cheema,Delvys Rodriguez-Abreu,Mirjana Wollner,James Chih-Hsin Yang,Julien Mazieres,Francisco Orlandi,Alexander Luft,Mahmut Gumus,Terufumi Kato,Gregory P. Kalemkerian,Yiwen Luo,Victoria Ebiana,M. Catherine Pietanza,Hye Ryun Kim,Keynote Investigators +20 more
TL;DR: Pembrolizumab plus EP significantly improved progression-free survival (PFS) and overall survival (OS) compared with placebo plus EP as first-line therapy for patients with ES-SCLC, and these data support the benefit of pembrolIZumab in ES-sCLC.